The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.
 
Jarushka Naidoo
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Merck; Pfizer; Roche/Genentech; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Kaleido Biosciences; Merck; Merck KGaA; Pfizer; Roche/Genentech; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Scott Joseph Antonia
Consulting or Advisory Role - Achilles Therapeutics; Amgen; AstraZeneca; Bristol-Myers Squibb; CBM Biopharma; Celsius Therapeutics; GlaxoSmithKline; Memgen; Merck; RAPT Therapeutics; Samyang; Venn Therapeutics
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; Celsius Therapeutics; GlaxoSmithKline; Merck; RAPT Therapeutics
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus therapeutics; Guardant Health; J INTS BIO; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - DAAN Biotherapeutics
 
Piruntha Thiyagarajah
Employment - AstraZeneca/MedImmune; Reckitt Benckiser (I)
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Helen Mann
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Michael David Newton
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Corinne Faivre-Finn
Travel, Accommodations, Expenses - AstraZeneca